Latest Convertible Notes News

Careteq Limited reported a disciplined operating cash flow in Q2 FY26 with strong growth in its Embedded Health Solutions segment and ongoing resolution of an ATO tax incentive dispute.

Audio Pixels has validated a major technical milestone for its digital MEMS speaker array and raised $1.25 million through convertible notes, while securing a $6 million funding commitment to support ongoing development amid continued ASX trading suspension.

CONNEQT Health Limited reported a strong quarter with over 200% sales growth for its CONNEQT Pulse product and completed a $3.1 million institutional placement, while operational cost reductions support a leaner business model.

Noumi Limited reported a 13.4% revenue increase in Q2 FY26 driven by strong growth in its Dairy and Nutritionals and Plant-based Milks segments, despite a $4.5 million operating cash outflow impacted by legal expenses. The company’s Milklab brand continues to gain traction both domestically and internationally.

Imugene Limited has reported compelling clinical trial results for its off-the-shelf CAR T therapy, azer-cel, alongside FDA validation and a strategic collaboration, while managing cash flow amid cost reductions.

Osteopore Limited reported a 30% year-on-year revenue increase in Q4 CY25, overcoming a slowdown in South Korea, and secured a strategic five-year partnership with DKSH Malaysia to expand its dental product reach.

QPM Energy has secured key contracts and financing milestones for its 112MW Isaac Power Station, while managing stable gas supply amid weak electricity prices.

Paradigm Biopharmaceuticals reports solid progress in its Phase 3 knee osteoarthritis trial, expanding internationally and publishing key Phase 2 biomarker data. The company maintains a robust cash position to support ongoing clinical milestones.

Noxopharm has successfully completed dosing in its HERACLES clinical trial for SOF-SKN™, demonstrating strong safety and tolerability. The company also secured a new overseas partnership and its first US patent for the Sofra platform.

Neurizon Therapeutics has cleared a major regulatory hurdle with the FDA lifting the clinical hold on its lead drug NUZ-001 and secured a comprehensive $33 million funding package to advance its pivotal ALS trial.

The Calmer Co has posted a record $2.01 million in sales for Q2 FY26, propelled by a 9% increase in US revenue which now accounts for over half of the group’s total income. Strong retail and wholesale growth underpin the company’s expanding footprint in the natural relaxation market.

The Calmer Co. International Limited has reported a second consecutive quarter of revenue exceeding $2 million, driven by strong U.S. growth and record monthly sales in December. The company’s strategic focus on wholesale and B2B extract channels underpins its confidence in reaching breakeven this fiscal year.